Chronic Obstructive Pulmonary Disease Treatment Market Surpass US$ 24.3 Bn By 2026

0
11

Global Chronic Obstructive Pulmonary Disease Treatment Market Size is anticipated to grow at 4.9 % CAGR during the forecast period and reach around US$ 24.3 Billion by 2026.

Recent study titled, Chronic Obstructive Pulmonary Disease Treatment Market By Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 – 2026 which covers clear verifiable examination and lights up feature components and examples that give an extensive picture of the business.

The Chronic Obstructive Pulmonary Disease Treatment Market Industry Report is an in depth study analyzing the current state of the Chronic Obstructive Pulmonary Disease Treatment Market. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Chronic Obstructive Pulmonary Disease Treatment Market provides analysis of China market covering the industry trends, recent developments in the market and competitive landscape. Competitive analysis includes competitive information of leading players in China market, their company profiles, product portfolio, capacity, production, and company financials. In addition, report also provides upstream raw material analysis and downstream demand analysis along with the key development trends and sales channel analysis. Research study on Chronic Obstructive Pulmonary Disease Treatment Market also discusses the opportunity areas for investors.

The study provides a decisive view of the market by segmenting it in terms of form and application. The segment has been analyzed based on present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1145

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding. Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.

Market Participants:

Main enterprises working in the global chronic obstructive pulmonary disease treatment market are Orion Corporation, AstraZeneca, Mylan N.V., BoehringerIngelheim Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc. and CHIESI Farmaceutici S.p.A.

The Major Market Segments of Global Chronic Obstructive Pulmonary Disease Treatment Market are as below:

Market Segmentation

Market By Drug Class

  • Bronchodilators
  • Combination
  • Phosphodiesterase Type 4 Inhibitors
  • Mucokinetics
  • Corticosteroids
  • Others

Market By Distribution Channel

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Market By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Regional Insights

Based on the region, the worldwide chronic obstructive pulmonary disease (COPD) treatment market has been classified into Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. North America represented the biggest revenue share of the worldwide market in 2018. Presence of built up pharmaceutical organizations, increment in adoption of new drugs propelled in the market, and concentrate on dispatch of new products through R&D are foreseen to drive the market in the area amid the estimate time frame.

The chronic obstructive pulmonary disease (COPD) treatment industry in Europe is driven by increment in R&D spending and introduction of new products. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. gotten approval from the European Commission for extended use for once-daily TrelegyEllipta, first single inhaler triple treatment demonstrated for COPD patients who were not enough treated with dual bronchodilation.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/chronic-obstructive-pulmonary-disease-treatment-market

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Chronic Obstructive Pulmonary Disease Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Chronic Obstructive Pulmonary Disease Treatment Market By Drug Class
1.2.2.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.2.2. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share By Drug Class in 2017
1.2.2.3. Bronchodilators
1.2.2.4. Combination
1.2.2.5. Phosphodiesterase Type 4 Inhibitors
1.2.2.6. Mucokinetics
1.2.2.7. Corticosteroids
1.2.2.8. Others
1.2.3. Chronic Obstructive Pulmonary Disease Treatment Market By Distribution Channel
1.2.3.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026)
1.2.3.2. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share By Distribution Channel in 2017
1.2.3.3. Online Pharmacies
1.2.3.4. Hospital Pharmacies
1.2.3.5. Retail Pharmacies
1.2.3.6. Others
1.2.4. Chronic Obstructive Pulmonary Disease Treatment Market by Geography
1.2.4.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017

CHAPTER 4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY DRUG CLASS

4.1. Global Chronic Obstructive Pulmonary Disease Treatment Revenue By Drug Class
4.2. Bronchodilators
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Combination
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Phosphodiesterase Type 4 Inhibitors
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.5. Mucokinetics
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.6. Corticosteroids
4.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.7. Others
4.7.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY DISTRIBUTION CHANNEL

5.1. Global Chronic Obstructive Pulmonary Disease Treatment Revenue By Distribution Channel
5.2. Online Pharmacies
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3. Hospital Pharmacies
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.4. Retail Pharmacies
5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.5. Others
5.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 6. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

6.1. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. U.S.
6.3.1. U.S. Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
6.5. Mexico
6.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
6.5.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)

CHAPTER 7. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

7.1. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
7.5.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
7.6.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
7.7.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

8.1. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
8.6.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
8.7.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
8.8.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)

CHAPTER 9. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

9.1. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
9.4. Argentina
9.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)

CHAPTER 10. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

10.1. Middle East Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Middle East Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Saudi Arabia
10.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
10.4. UAE
10.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
10.5. Rest of Middle East
10.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)

CHAPTER 11. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

11.1. Africa Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Africa Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. South Africa
11.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
11.4. Egypt
11.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)
11.5. Rest of Africa
11.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Orion Corporation
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. AstraZeneca
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. Mylan N.V.
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. BoehringerIngelheim Pharmaceuticals, Inc.
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Teva Pharmaceutical Industries Ltd.
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. GlaxoSmithKline plc
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Novartis AG
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Sunovion Pharmaceuticals, Inc.
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. CHIESI Farmaceutici S.p.A.
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Others
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

To Purchase this Premium Report at https://www.acumenresearchandconsulting.com/buy-now/0/1145

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

LEAVE A REPLY

Please enter your comment!
Please enter your name here